← All indications
Acromegaly
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
Drugs by status
Approved for this indication (10)
Phase 4 trials (4)
Phase 3 trials (1)
Phase 2 trials (10)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (14)
- Pfizer
- Aarhus University
- Julius-Maximilians University
- John Wayne Cancer Institute
- Norwegian University of Science and Technology
- University of Southern Denmark
- Aalborg University
- Columbia University
- University of Copenhagen
- University of Naples Frederico II
- University of Ulsan
- Ludwig Maximilians University
- University of Genoa
- Erasmus University Rotterdam
Organization Involved with Phase 3 Indications (12)
- Ambrilia Biopharma, Inc.
- Camurus AB
- Chiasma, Inc.
- Endo Pharmaceuticals
- National Institutes of Health (NIH)
- National Institute of Dental and Craniofacial Research (NIDCR)
- Baylor University
- Cedars-Sinai Medical Center
- Oregon Health and Science University
- University of Toronto
- University of Duisburg-Essen
- Sungkyunkwan University
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (10)